Poster Presentation at ASH

The following abstract is scheduled to be presented at ASH as follows:

Abstract #1563: "A Phase I/II Trial of the Kinesin Spindle Protein (KSP)Inhibitor SB-743921 Administered on Days 1 and 15 Every 28 Days without andwith Prophylactic G-CSF in Non-Hodgkin or Hodgkin Lymphoma." The posterpresentation is on Saturday, December 6, 2008 during the Lymphoma:Chemotherapy and Clinical Trials Poster Session, and the presenter, JohnGerecitano, M.D. Memorial Sloan-Kettering Cancer Center, New York, NY, willbe present from 5:30 PM - 7:30 PM Pacific at board # I-668.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery,development and commercialization of novel small molecule drugs that mayaddress areas of significant unmet clinical needs. Cytokinetics'cardiovascular disease program is focused to cardiac myosin, a motorprotein essential to cardiac muscle contraction. Cytokinetics' leadcompound from this program, CK-1827452, a novel small molecule cardiacmyosin activator, entered Phase II clinical trials for the treatment ofheart failure in 2007. Under a strategic alliance established in 2006,Cytokinetics and Amgen Inc. are performing joint research focused onidentifying and characterizing activators of cardiac myosin as back-up andfollow-on potential drug candidates to CK-1827452. Amgen has obtained anoption for an exclusive license to develop and commercialize CK-1827452,subject to Cytokinetics' development and commercial participation rights.Cytokinetics' cancer program is focused on mitotic kinesins, a family ofmotor proteins essential to cell division. Under a strategic allianceestablished in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conductingresearch and development activities focused on the potential treatment ofcancer. Cytokinetics is developing two novel drug candidates that havearisen from this program, ispinesib andSB-743921, each a novel inhibitor of kinesin spindle protein (KSP), amitotic kinesin. Cytokinetics is conducting the Phase I portion of a PhaseI/II clinical trial of ispinesib as monotherapy as a first-line treatmentin chemotherapy-naïve patients with locally advanced or metastatic breastcancer. In addition, Cytokinetics is conducting the Phase I portion of aPhase I/II trial ofSB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has anoption for the joint development and commercialization of ispinesib andSB-743921. GSK-923295, an inhibitor of centromere-associated protein E(CENP-E) inhibitor, is being developed under the strategic alliance by GSK;GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008,Cytokinetics announced the selection of a potential drug candidate directedtowards skeletal muscle contractility which may be developed as a potentialtreatment for skeletal muscle weakness associated with neuromusculardiseases or other conditions. All of these drug candidates and potentialdrug candidates have arisen from Cytokinetics' research activities and aredirected towards the cytoskeleton. The cytoskeleton is a complex biologicalinfrastructure that plays a fundamental role within every human cell.Additional information about Cytokinetics can be obtained atwww.cytokinetics.com.

This press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act"). Cytokineticsdisclaims any intent or obligation to update these forward-lookingstatements, and claims the protection of the Safe Harbor forforward-looking statements contained in the Act. Examples of suchstatements include, but are not limited to, statements relating toCytokinetics' and its partners' research and development activities, futurepresentations concerning Cytokinetics' research and development programs,the potential benefits of Cytokinetics' drug candidates and potential drugcandidates and the enabling capabilities of Cytokinetics' cytoskeletalfocus. Such statements are based on management's current expectations, butactual results may differ materially due to various risks anduncertainties, including, but not limited to, potential difficulties ordelays in the development, testing, regulatory approval, production andmarketing of Cytokinetics' drug candidates that could slow or preventclinical development, product approval or market acceptance, includingrisks that current and past results of clinical trials or preclinicalstudies may not be indicative of future clinical trials result; patientenrollment for clinical trials may be difficult or take longer thananticipated; Cytokinetics' drug candidates may have unexpected adverse sideeffects or inadequate therapeutic efficacy, the U.S. Food and DrugAdministration or foreign regulatory agencies may delay or limitCytokinetics' or its partners' ability to conduct clinical trial;Cytokinetics may be unable to obtain and maintain patent or trade secretprotection for its intellectual property; potential decisions by GSK topostpone or discontinue development efforts for GSK-923295 or not exerciseits options to ispinesib orSB-743921; Cytokinetics may incur unanticipated research and developmentand other costs or be unable to obtain additional financing if necessary;standards of care may change rendering our products; others may introduceproducts or alternative therapies for the treatment of indicationsCytokinetics' drug candidates and potential drug candidates currently orpotentially target; and risks and uncertainties relating to the timing andreceipt of funds under Cytokinetics' collaborations. For furtherinformation regarding these and other risks related to Cytokinetics'business, investors should consult Cytokinetics' filings with theSecurities and Exchange Commission.

Contacts:Christopher S. Keenan (Investors)Director, Investor Relations(650) 624-3000